Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial. - Publikation

Publikation

Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial.

Wissenschaftlicher Artikel/Review - 28.05.2022

Dal Pra Alan, Ghadjar Pirus, Hayoz S, Liu V Y T, Spratt D E, Thompson D J S, Davicioni E, Huang H-C, Zhao X, Liu Yali, Scharf Christop, Gut P, Plasswilm Ludwig, Hölscher Tobias, Polat Bülent, Hildebrandt G, Müller A-C, Pollack A, Thalmann G N, Zwahlen D, Aebersold D M

Zitation

Dal Pra A, Ghadjar P, Hayoz S, Liu V, Spratt D, Thompson D, Davicioni E, Huang H, Zhao X, Liu Y, Scharf C, Gut P, Plasswilm L, Hölscher T, Polat B, Hildebrandt G, Müller A, Pollack A, Thalmann G, Zwahlen D, Aebersold D. Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial. Ann Oncol 2022; 33:950-958.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Ann Oncol 2022; 33

Veröffentlichungsdatum

28.05.2022

eISSN (Online)

1569-8041

Seiten

950-958

Kurzbeschreibung/Zielsetzung

The Decipher genomic classifier (GC) has shown to independently prognosticate outcomes in prostate cancer. The objective of this study was to validate the GC in a randomized phase III trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy.